Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Lifesciences gets USFDA nod for asthma treatment drug
Details : Theophylline generic extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Brand Name : Theo-Dur-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : DeepWork Capital
Deal Size : $9.0 million
Deal Type : Series B Financing
Details : Cyrano intends to use the proceeds to advance FLAVOR, its Phase 2, double-blind, randomized clinical trial of CYR-064, an intranasal theophylline spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection...
Brand Name : CYR-064
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : DeepWork Capital
Deal Size : $9.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?